Antibiotic - EV-035




What they say about it

EV-035 is a novel bacterial type II topoisomerase inhibitor, belonging to the chemical class of 2-pyridones. EV-035 shows excellent broad-spectrum activity, including pathogens such as Staphylococcus, Streptococcus, Enterococcus, Escherichia, Pseudomonas, Acinetobacter and Haemophilus. Most importantly, EV-035 shows activity not only on drug-sensitive strains, but also on those resistant to marketed antibiotics (including quinolones) and has a very low propensity of developing new resistance. EV-035 has a very favourable in vitro safety profile and its pharmacokinetic properties allow for intravenous as well as oral dosing. The spectrum of EV-035 also extends to potential biothreat agents such as Burkholderia pseudomallei, Burkholderia mallei, Yersinia pestis, Bacillus anthracis, Francisella tularensis and Brucella abortus, work which was part-funded by the US Department of Defense. Evolva owns all rights to EV-035 and has patent applications covering this portfolio. Source 1 Source 2

Country of Origin

How they say it works

Genetically modified yeast fermentation.

Market Status

Synbio Components